FDA Approves Kerendia (finerenone) for the Treatment of Patients with Chronic Kidney Disease Associated with Type 2 Diabetes

WHIPPANY, N.J.-- July 9, 2021 (BUSINESS WIRE)-- Bayer announced today the United States (U.S.) Food and Drug Administration (FDA) has approved Kerendia (finerenone), a first-in-class nonsteroidal mineralocorticoid receptor antagonist (MRA) indicated...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news